Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2026 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/13/2025 | $22.00 | Outperform | Leerink Partners |
| 9/25/2025 | $20.00 | Outperform | Leerink Partners |
| 6/20/2025 | Outperform | William Blair | |
| 10/22/2024 | $32.00 | Outperform | Robert W. Baird |
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 23,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasdaq
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share. In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,102,040 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts a
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A common stock. In addition, Contineum intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. All securities in the proposed offering are to be sold by Contineum. The proposed offering is subject to mark
Morgan Stanley downgraded Contineum Therapeutics from Overweight to Equal-Weight and set a new price target of $14.00
Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $22.00
Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $20.00
SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe